改造的纤维细胞生长因子1变体,从代性活动中脱离降糖效应,具有治疗2型糖尿病的治疗潜力
Aleksandra A Czyrek1,2,3,4, Daniel Krowarsch1, Szymon Sidor1
1Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, Wroclaw, 50-383, Poland.
Molecular biomedicine
|January 10, 2026
概括
工程纤维细胞生长因子1 (FGF1) 变种有效降低血糖,用于2型糖尿病治疗. 这些修改后的FGF1蛋白降低了不必要的细胞增殖,同时保持了强大的降糖效应.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 纤维细胞生长因子1 (FGF1) 在2型糖尿病模型中有效降低血糖.
- FGF1的临床使用受到其显著的线粒体发生 (细胞增殖) 潜力所限制.
研究的目的:
- 设计FGF1变体,将降血糖效应与毒性活动分开.
- 为2型糖尿病开发稳定安全的基于蛋白质的治疗候选药物.
主要方法:
- 引入了理性突变来调节FGF1受体结合和肝素相互作用.
- 在体外研究中评估了细胞类型的线粒生成潜力.
- 在db/db小鼠的体内研究评估了降血糖效果,低血糖和体重变化.
- 分析了热力学稳定性和药物动力学概况.
主要成果:
- 与野生类型的FGF1.1相比,工程FGF1变种显示出显著降低的真菌致病潜力.
- 一种变体由于FGFR结合中断而失去了增殖;另一个变体由于降低肝素亲和力而减弱了线粒发生力.
- 这两种变体在db/db小鼠中都保持了强烈的降血糖效应,没有任何不良影响.
- 观察到增强的热力学稳定性和改善的药物动力学概况.
结论:
- 开发了一种成功的策略,将FGF1的治疗益处与其线索性副作用分开.
- 工程FGF1变体代表了2型糖尿病治疗的有希望的药物候选者.
- 这些变体为基于FGF1的治疗提供了更安全,更稳定的方法.
相关概念视频
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
Dipeptidyl Peptidase 4 Inhibitors
574
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574


